Biohaven (BHVN) PT Raised to $85 at Mizuho Securities on Solid Nurtec ODT Launch Execution
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $85.00 (from $53.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
